Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)

Patent metadata

Field	Value
Publication number	US-12208093-B2
Application number	US-202217669425-A
Country	US
Kind code	B2
Filing date	Feb 11, 2022
Priority date	Jan 4, 2016
Publication date	Jan 28, 2025
Grant date	Jan 28, 2025

Abstract

The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.

First claim

We claim:

1. A synergistic pharmaceutical composition comprising (a) emetine; (b) a human cytomegalovirus (HCMV) drug selected from the group consisting of ganciclovir, valganciclovir, maribavir, foscarnet and cidofovir; and (c) a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition further comprises an adjuvant.

3. A method for treating HCMV in a patient in need thereof comprising administering to the patient the synergistic pharmaceutical composition of claim 1 .

4. A method for treating HCMV in a patient in need thereof comprising administering to the patient a therapeutically effective amount of emetine in combination with a human cytomegalovirus (HCMV) drug selected from the group consisting of ganciclovir, valganciclovir, maribavir, foscarnet and cidofovir, wherein the combination has synergistic effect in treating HCMV.

Assignees

• Univ Johns Hopkins
• The Us Secretary Department Of Health And Human
• The United States Of America Represented By The Sec Dep Of Health And Human Services

Inventors

• Boger Ravit
• Ferrer Marc
• MARUGAN Juan
• Garcia Andres Dulcey
• Southall Noel Terrence
• Hu Xin

Classifications

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61K9/0019

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61P31/22

  for herpes viruses · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title